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Estrogen receptor a (ERa) is the key transcriptional
driver in a large proportion of breast cancers. We
report that APOBEC3B (A3B) is required for regula-
tion of gene expression by ER and acts by causing
C-to-U deamination at ER binding regions. We
show that these C-to-U changes lead to the genera-
tion of DNA strand breaks through activation of base
excision repair (BER) and to repair by non-homolo-
gous end-joining (NHEJ) pathways. We provide evi-
dence that transient cytidine deamination by A3B
aids chromatin modification and remodelling at the
regulatory regions of ER target genes that promotes
their expression. A3B expression is associated with
poor patient survival in ER+ breast cancer, rein-
forcing the physiological significance of A3B for ER
action.INTRODUCTION
Estrogens play a central role in promoting breast cancer devel-
opment (Ali and Coombes, 2002) and are important in uterine
and ovarian cancer (O’Donnell et al., 2005; Shang, 2006). Two
closely related nuclear receptors, estrogen receptor a (ERa,
herein referred to as ER) and ERb, mediate estrogen actions
(Dahlman-Wright et al., 2006). ERa is dominant in breast cancer;
70% of breast cancers express ERa, and therapies to inhibit its
activity have transformed breast cancer treatment. However,
many patients develop resistance, with few treatment options
being available for endocrine-therapy-resistant breast cancer
(Osborne and Schiff, 2011).
Gene expression profiling and approaches for genome-wide
identification of ER binding regions have allowed the identifica-
tion of direct ER targets in breast cancer cells and highlight the108 Cell Reports 13, 108–121, October 6, 2015 ª2015 The Authorsimportance of pioneer factors, particularly FOXA1 and GATA3
in directing ER by promoting chromatin accessibility and long-
range chromatin interactions (Magnani et al., 2011; Ross-Innes
et al., 2012). Critical for transcription regulation by ER is the or-
dered recruitment of a multitude of transcriptional co-regulator
complexes with enzymatic activities for histone modification
and chromatin remodeling (Me´tivier et al., 2006), which promote
short- and long-range protein-DNA and protein-protein interac-
tions between enhancer regions and gene promoters, to facili-
tate expression of ER target genes that drive breast cancer cell
proliferation. The processes of transcription and DNA repair
are intimately linked, as defined most obviously for the basal
transcription factor TFIIH, which is essential for transcription
initiation by RNA polymerase II (PolII), but is also required for
the transcription-coupled nucleotide excision repair (Compe
and Egly, 2012; Kamileri et al., 2012). Other DNA repair pathways
also aid transcription (Fong et al., 2013) by promoting active DNA
demethylation (Bhutani et al., 2011; Nabel and Kohli, 2011),
enhancer RNA (eRNA) synthesis (Puc et al., 2015), and chromatin
remodeling (Ju et al., 2006; Perillo et al., 2008), through pro-
cesses that can involve the generation of single- and double-
strand DNA breaks at enhancer regions.
The AID/APOBEC genes comprise a family of enzymes that
mutate RNA or DNA by deaminating cytidine to uridine. Among
their functions are RNA editing of the apolipoprotein B pre-
mRNA by APOBEC1 and generation of antibody diversity by
class-switch recombination and somatic hypermutation through
DNA editing by AID (Conticello, 2008). In primates, there are
seven closely related APOBEC3 genes, some of which function
in retroviral restriction by promoting ‘‘hypermutation’’ in viral ge-
nomes. These functions do not readily explain the potential roles
of APOBEC3 genes in non-immune system tissues, including
breast, lung, cervix, bladder, and ovary, or the overexpression
of some members of the family in cancers from these tissues
(Burns et al., 2013a, 2013b; Leonard et al., 2013), although a po-
tential role in the repair of DNA double-strand breaks (DSBs), re-
sulting in resistance of lymphoma cells to ionizing radiation, has
been ascribed to APOBEC3G (Nowarski et al., 2012). Interest-
ingly, ectopic expression of APOBEC3A (A3A) and A3B can pro-
mote mutagenesis in cancer cells (Burns et al., 2013a; Landry
et al., 2011; Taylor et al., 2013).
Cancer genomes are marked by an accretion of somatic mu-
tations. Recent whole-genome sequencing of breast cancer
has yielded genome-wide mutational signatures, one of which
is consistent with the DNAmutation profiles associated with cyti-
dine deamination by APOBEC3 genes (Alexandrov et al., 2013;
Nik-Zainal et al., 2012). Similar mutational signatures have
been described in ovarian, bladder, cervical, head and neck,
and lung cancer (Burns et al., 2013a, 2013b; de Bruin et al.,
2014; Leonard et al., 2013; Roberts et al., 2013). A3B expression
is frequently elevated in breast and other cancers that feature
mutational landscapes consistent with cytidine deaminase activ-
ity (Burns et al., 2013a, 2013b). This, together with the demon-
stration that ectopic A3B expression can promote C-to-T muta-
tions in breast cancer cells, has led to a proposedmodel in which
A3B overexpression in breast cancer could aid tumor initiation
and progression by driving somatic mutations in cancer. How-
ever, breast cancers from patients featuring a germline copy-
number polymorphism involving A3A and A3B, in which A3B is
effectively deleted, carry a greater burden of mutations associ-
ated with the APOBEC-dependent signature than those in which
the A3A and A3B genes are intact (Nik-Zainal et al., 2014),
bringing into question the importance of A3B in this process.
To investigate the potential role of A3B in breast cancer, we
analyzed its expression in breast cancer. Surprisingly, A3B
expression was associated with poor patient survival in ER+
breast cancer, but not in ER breast cancer, despite the fact
that A3B expression was higher in ER breast cancer than in
ER+ breast cancer, thus implicating A3B in ER action. Here,
we provide evidence for a molecular mechanism in which A3B
causes local and transient C-to-U transitions at ER enhancers,
leading to activation of base excision repair (BER) and non-ho-
mologous end-joining (NHEJ) pathways, which in turn promote
chromatin modification and remodeling, to drive expression of
ER target genes.
RESULTS
A3B Expression Is Associated with Poor Prognosis
in ER+ Breast Cancer
AID/APOBECs function in retroviral restriction and in the case of
AID, in class-switch recombination and somatic hypermutation
to generate antibody diversity by causing C-to-T mutations
(Conticello, 2008), functions that do not explain the high-level
expression of A3B in many cancers (Burns et al., 2013a,
2013b). Toward defining the role of A3B in breast cancer sub-
types, we determined the relationship between A3B levels and
patient outcome. Analysis of the METABRIC (Curtis et al.,
2012) series of 2,000 breast cancer patients revealed that high
A3B expression is associated with poor survival (hazard ratio
[HR] = 1.5, p = 1 3 1011) (Figures S1A and S1B). Interestingly,
A3B expression was associated with poor outcome in ER+
(HR = 1.9; p = 4.5 3 1011) (Figure 1A), but not in ER (p =
0.18), breast cancer. A3B retained its significance (HR = 1.59,
p = 1.27 3 106) in multivariate analysis of ER+ breast cancerC(Figure S1C). There was no association between expression of
other APOBECs and poor outcome in ER+ or ER breast cancer
in the METABRIC dataset (data not shown). We extended this
analysis to other gene expression microarray datasets. Kaplan-
Meier plot analysis of Affymetrix microarray datasets similarly
showed that high A3B expression is associated with poor
outcome for ER+, but not ER, breast cancer (Figures S1D–
S1F). Forest-plot analysis for relapse-free survival further
confirmed the importance of A3B in ER+ breast cancer (Fig-
ure 1B). Real-time RT-PCR for 151 breast cancers again
confirmed that A3B is expressed in ER+ and ER breast cancer,
as well as in the majority of breast cancer cell lines examined
(Figures 1C and S1G–S1R), in agreement with previous findings
(Burns et al., 2013a).
A3B Regulates the Growth of ER+ Breast
Cancer Cells
Given the association between A3B expression and poor patient
survival in ER+ breast cancer, we wondered whether A3B regu-
lates the growth of ER+ breast cancer cells. To investigate this,
we treated tumor xenografts of the ER+ and estrogen-regulated
MCF7 breast cancer cell line, which expresses moderate levels
of A3B, with A3B small interfering RNA (siRNA). A3B knockdown
markedly inhibited MCF7 tumor growth (Figure 1D), demon-
strating that A3B is required for MCF7 tumor growth in vivo.
Remarkably, ER target gene expression was greatly reduced in
these tumors (Figures 1E and 1F), suggesting that A3B impacts
directly on ER function. Indeed, transfection of MCF7 cells in
culture with two independent A3B siRNAs inhibited estrogen-
stimulated growth, accompanied by reduced expression of ER
regulated genes (Figures S2A–S2C). Inhibition of estrogen-regu-
lated growth and estrogen-responsive gene expression was
confirmed in a second ER+ cell line (T47D) (Figures 1G and
1H). SkBr3 cells, which are null for A3B (Komatsu et al., 2008),
were not affected by A3B siRNA (Figures S1I and S2D). Growth
of the A3B+/ER MDA-MB-231 cells was also unaffected by
A3B siRNA (Figure S2E). Furthermore, inhibition of ER target
gene expression by a siRNA targeting the A3B 30-UTR was
rescued by transfection of an A3B expression plasmid that lacks
the 30 UTR. However, siRNAs targeting the A3B coding region
knocked down endogenous and ectopic A3B and inhibited ER-
regulated genes (Figures S2F and S2G). Taken together, these
results demonstrate A3B specificity of the siRNAs and show
that A3B regulates growth and expression of estrogen-respon-
sive genes in breast cancer cells.
A3B Is Recruited Globally to ER Binding Regions,
and This Requires Its Interaction with the ER
Next, we sought to determine whether A3B is required for the ER
transcriptional response. In a reporter gene assay, A3B stimu-
lated ER activity (Figures 2A and 2B). A3B contains two zinc
coordinating cytidine deaminase activity (CDA) domains (Conti-
cello, 2008). Substitution of glutamic acid residues at positions
68 or 255 to glutamine, which inhibits the cytidine deaminase ac-
tivity in the N- and C-terminal domains of A3B, respectively,
reduced stimulation of ER activity. Hence, both CDA domains
are required for modulation of ER activity by A3B, echoing a
previous report, which showed that both CDA domains areell Reports 13, 108–121, October 6, 2015 ª2015 The Authors 109
Figure 1. A3B Regulates ER Activity to Promote Breast Cancer Cell Growth
(A) Kaplan-Meier plots of breast cancer survival for ER+ patients from METABRIC, according to A3B expression.
(B) Forest plot analysis of ER+ breast cancers for A3B expression. Affymetrix microarray datasets that included >100 ER+ breast cancers were used in the
analysis: E-MTAB-365 (Guedj et al., 2012), GSE7390 (Desmedt et al., 2007), GSE3494 (Miller et al., 2005), GSE21653 (Sabatier et al., 2011), GSE2034 (Wang et al.,
2005), and GSE12093 (Zhang et al., 2009). Hazard ratios and 95% confidence intervals are plotted on the x axis.
(C) Real-time RT-PCR was carried out using RNA prepared from ER+ (n = 92) and ER (n = 49) breast cancers. Also shown are the expression profiles for ER+
breast cancer cell lines, with MCF7 and T47D expression highlighted.
(D) MCF7 tumors were treated weekly with vehicle (n = 6), control siRNA (n = 6), or A3B siRNA (n = 6). Mean tumor volumes are plotted ± SEM. RNA and protein
were prepared from tumors at the end of the experiment.
(E) Real-time RT-PCR relative to GAPDH levels (n = 3; p < 0.0001) for tumors.
(F) Immunoblotting of protein lysates (20 mg) tumors is shown.
(G) Hormone-depleted T47D cells transfected with A3B siRNAs were assessed for growth (n = 4).
(H) mRNA levels were determined following transfection of hormone-depleted T47D cells with A3B siRNAs. mRNA expression is shown relative to the expression
for the siControl samples (n = 3). Statistical significance within each treatment group for each A3B siRNA relative to siControl is denoted by asterisks (p < 0.001).
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Figure 2. A3B Interacts with ER and Is Recruited to ER Binding Regions
(A) Schematic representation of A3B. Highlighted are the catalytic site mutations used here.
(B) COS-1 cells cultured in hormone-free medium were transfected with an estrogen-responsive luciferase reporter gene, ER and A3B. Estrogen (10 nM) was
added for 20 hr. Data are shown as fold activation, relative to reporter activity for vehicle treatment, following co-transfection of ER without A3B (vector control)
(n = 3; * = p < 0.05). Immunoblotting for ER and A3B following transfection of COS-1 cells is also shown.
(C) Hormone-depleted MCF7 cells treated with estrogen were immunoprecipitated with an ER antibody. Input represents 10% of lysate used in the immuno-
precipitations.
(legend continued on next page)
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enzymatically active and contribute to C-to-T editing (Bogerd
et al., 2007). A3B was co-immunoprecipitated with ER in MCF7
cells (Figure 2C), and chromatin immunoprecipitation (ChIP) as-
says showed that A3B is recruited, in an estrogen-dependent
manner, to the ER binding regions in the TFF1 and GREB1 genes
(Figures 2D and S3A). AIB1, which interacts with ER in an estro-
gen-dependent manner (Anzick et al., 1997), acts as a control.
ChIP sequencing (ChIP-seq), for A3B to define the global dis-
tribution of A3B on chromatin, identified 24,486 binding sites in
MCF7 cells treated with estrogen (Figures 2E and S3B). A3B
binding was primarily observed at intronic and gene-distal re-
gions (Figure S3C), suggesting that A3B binding occurs in
gene regulatory regions. ChIP-seq for ER has established that
the great majority of ER binding events also map to sites within
introns and at considerable distances upstream and down-
stream of transcribed regions (Welboren et al., 2009). Analysis
of the raw reads demonstrated a remarkably close genomic
co-localization of the binding sites for the two proteins (r2 =
0.96) (Figure 2F). A3B binding sites were significantly enriched
in the vicinity of estrogen-responsive genes (Figure 2G) and
were enriched in binding motifs for ER (Figure 2H; Table S1).
Alignment of all ER binding sites showed that the majority of
ER binding sites in MCF7 cells are bound by A3B and that estro-
gen treatment results in global stimulation of A3B recruitment to
ER binding regions (Figures 2I and 2J), as evident from the
genome browser snapshots for the ER target genes TFF1,
GREB1, FOS, and CTSD (Figure 2K). These results provide a
compelling argument for a mechanism of chromatin-based
collaboration between A3B and ER, toward the global regulation
of ER target genes in breast cancer.
Recovering the chromatin following ChIP for ER and perform-
ing ChIP with A3B antibody (ChIP/reChIP) showed that ER and
A3B are present concurrently at the TFF1 ERE (Figure 2L).
ChIP for A3B followed by reChIP for ER provided similar results.
Treatment of MCF7 cells with the anti-estrogen fulvestrant (aka
ICI182,780), which specifically promotes the downregulation of
ER protein (McClelland et al., 1996), resulted in ER loss and
lack of ER binding to chromatin in ChIP assays (Figures 2L and
S3D). Fulvestrant did not affect A3B protein levels, but A3B
recruitment to the TFF1 and PDZK1 ER binding regions was(D) MCF7 cells were treated with estrogen (10 nM, 45 min), followed by ChIP. Sh
proximal ERE or a control region in the TFF1 gene to which ER binding is not ob
(E) A3BChIP-seqwas carried out following treatment of MCF7 cells with 10 nM es
calling analysis.
(F) Genome-wide enrichment correlation analysis for A3B and ER raw signals dem
ChIP-seq reads were normalized (wig file) and binned in windows of 100 kb wh
genome-wide correlation using a Spearman’s correlation score. The score for ea
(G) Analysis of A3B binding regions identified by ChIP-seq are significantly enric
(H) Analysis of the relative enrichment of transcription factor binding sites was use
cloud.
(I) Average signal intensity of A3B ChIP-seq binding events, centered on ER bindin
upon estrogen treatment. Signal intensity is a normalized count of individual, no
calling algorithm (MACS 1.4)
(J) Heatmap showing clustered binding signal for A3B ± estrogen. The window re
scale represents relative enrichment based on raw signal.
(K) Representative genome browser snapshots show A3B binding regions and o
(L) ChIP with ER or A3B antibodies (denoted by ) was followed by recovery of
immunoglobulins (IgG control) (n = 3).
(M) MCF7 cells were treated with fulvestrant for 24 hr, followed by addition of es
112 Cell Reports 13, 108–121, October 6, 2015 ª2015 The Authorsnevertheless prevented. By contrast, siRNA-mediated A3B
knockdown did not affect ER recruitment (Figure S3E). Thus,
although A3B interacts with ER in a ligand-independent manner,
its recruitment to chromatin is estrogen dependent by virtue of
estrogen-stimulated recruitment of ER to chromatin. Further-
more, given that A3B is not required for ER recruitment to
DNA, A3B is unlikely to act as a pioneer factor.
A3BPromotes Cytidine Deamination to Generate C-to-U
Transitions at ER Binding Regions in Breast Cancer
Cells
Mutational inactivation of the A3B catalytic domains inhibited ER
stimulation in reporter gene assays (Figure 2A), implying that
deamination of deoxycytidine to deoxyuridine (C to U) is required
for the regulation of estrogen-responsive gene expression by
A3B. We used differential DNA denaturation PCR (3D-PCR),
which identifies C-to-T changes, based on detecting PCR ampli-
cons at lower denaturation temperatures arising froman increase
in A/T content (Burns et al., 2013a; Suspe`ne et al., 2005), to deter-
mine if A3B causes C-to-U changes at ER binding regions. Estro-
gen treatment of MCF7 cells generated lower-temperature
amplicons in the TFF1 promoter region (Figure 3A). Cloning and
sequencing of the PCR products from three independent exper-
iments identifiedC-to-T changes in a total of 12/109 (11%) clones
from vehicle-treated cells, increasing to 43/114 (38%) following
estrogen treatment (Figure 3B). Importantly, the overwhelming
majority (37/43 [86%]) of these changesmapped to theA3Bbind-
ing region (Figure 3C). Sequencing of 3D-PCRproducts following
A3B knockdown identified C-to-T changes in a total of 58/155
(37%) clones in siControl-transfected, compared with 13/163
(8%) clones in siA3B-transfected, MCF7 cells (Figures 3D and
3E), demonstrating that A3B is necessary for the C-to-U transi-
tions as the TFF1 ER/A3B binding region. Similar results were
obtained for the PDZK1 ER/A3B binding region, if A3B was
knocked down in T47D cells (Figures S4A–S4E).
Failure to repair cytidine deamination would result in the accu-
mulation of deleterious mutations at gene enhancers. As dU is
excised by uracil DNA glycosylase (UNG) (Stavnezer, 2011),
we determined if UNG is required for the A3B-dependent
cytidine deamintion at ER binding regions. UNG knockdownown are the results of real-time PCR of ChIP DNA for the TFF1 gene promoter
served (n = 3).
trogen for 45min. The Venn diagram shows A3B binding regions from the peak-
onstrates correlation (r2 = 0.96) between A3B and ER binding sites. A3B and ER
ere the average score was calculated. The data were then used to calculate
ch window is plotted and an interpolation line added to ease interpretation.
hed in the proximity of estrogen responsive genes.
d to generate a Z score, which is represented by the size of the motif in the word
g regions, shows increased recruitment of A3B to ER binding regions globally,
n-redundant ChIP fragments at single ER binding sites identified by the peak-
presents ±2.5-kb regions from the center of the ER binding events. The color
verlap with ER binding regions, shown on the same scale.
the chromatin complexes and reChIP with antibodies for A3B, ER, or mouse
trogen for 45 min (n = 3).
Figure 3. Estrogen Treatment Induces A3B-Dependent C-to-U Transitions at the ER and A3B Binding Region in the TFF1 Gene
(A) Genomic DNA was prepared fromMCF7 cells treated with 10 nM estrogen for 45 min. Agarose gel analysis of 3D-PCR for the TFF1 promoter region is shown.
(B) Mutation analysis of 3D-PCR amplicons from vehicle- and estrogen-treated cells is represented as a percentage of clones harboring C-to-T changes. Clones
from three independent experiments were sequenced, for a total of >100 clones per treatment.
(C) Each identified C-to-T transition is shown (blue dots), mapped to the region of the TFF1 gene (520 to +80) amplified by 3D-PCR.
(D) MCF7 cells transfected with A3B or control siRNA were treated with estrogen as described above.
(E) 3D-PCR amplicons were cloned. Shown are the percentage of clones harboring C-to-T transitions for a total of >150 clones generated from three experiments.
(F) 3D-PCR of genomic DNA from MCF7 cells transfected with UNG siRNA were treated with estrogen.
(G) Hormone-depleted MCF7 and T47D cells transfected with siUNG were assessed for growth in the presence or absence of estrogen (*p < 0.001; n = 4).
(H) Real-time PCR using RNA prepared from MCF7 cells transfected with siUNG, following 12 hr treatment with estrogen (10 nM) (*p < 0.001; n = 3).
(I) HeLa cells cultured in hormone-free medium were transfected with an estrogen-responsive luciferase reporter gene, together with ER, A3B, and myc-UGI
(n = 3). Immunoblotting is shown in the inset.
(J) MCF7 cells transfected with myc-UGI were treated with estrogen for 12 hr, and RNA and protein were isolated. Real-time PCR and immunoblotting for ER
target genes are shown.
(K) Hormone-depleted MCF7 and T47D cells transfected with myc-UGI were grown in the presence or absence of estrogen for 5 days. Growth was measured
using the sulforhodamine B (SRB) assay (*p < 0.001; n = 4).resulted in lower-temperature amplicons at ER/A3B binding re-
gions (Figure 3F), suggesting that lack of UNG ‘‘fixes’’ the A3B
directed C-to-U changes in DNA. The consequence of UNG
knockdown was inhibition of ER target gene expression and
MCF7 and T47D cell growth (Figures 3G, 3H, and S4F).
We used the bacteriophage PBS2 uracil DNA glycosylase in-
hibitor (UGI), which represses UNG activity in mammalian cells
(Burns et al., 2013a), to confirm the involvement of UNG. In a re-
porter gene assay, ectopic expression of UGI prevented the
stimulation of ER activity by A3B (Figure 3I). UGI transfection
also repressed endogenous ER target gene expression and
estrogen-stimulated growth of MCF7 and T47D cells (FiguresC3J, 3K, and S4G). Finally, ChIP showed that UNG was recruited
to ER binding regions in the TFF1 and PDZK1 genes, its recruit-
ment being prevented by A3B knockdown (Figures 4A–4C).
Thus, UNG is required for ER function and is recruited to ER
binding sites in an A3B-dependent manner. Importantly, these
results indicate that repair of A3B driven cytidine deamination in-
volves the action of UNG.
Estrogen Binding to ER Promotes DNA Strand Breaks at
ER Binding Regions
The mechanism of immunoglobulin gene class switch recombi-
nation involves cytidine deamination by AID and subsequentell Reports 13, 108–121, October 6, 2015 ª2015 The Authors 113
Figure 4. Estrogen Treatment of MCF7
Cells Induces DSBs at ER Binding Regions
Hormone-depleted MCF7 cells were used in all
experiments.
(A and B) ChIP for A3B, UNG, DNA-PKcs, and
Ku70 was performed following estrogen addition
to MCF7 cells transfected with siA3B or siControl.
Real-time PCR was performed on recovered DNA,
using primers flanking the ER binding regions in
TFF1 and PDZK1 genes (n = 3, *p < 0.001).
(C) A3BmRNA levels by real-time PCR for samples
used above.
(D) Estrogen was added and cells were immuno-
stained for gH2AX. Nuclei were visualized with the
TOPRO DNA stain.
(E) gH2AX in 100 cells from five replicates (total
n = 500) was quantified using Cell Profiler 2.0.
(F) OHT or FUL was added for 1 hr, followed by
addition of estrogen (E2) for 10 min. Boxplots
show the mean gH2AX foci number in 100 cells
(n = 5).
(G) gH2AX ChIP (MCF7) and real-time PCR for the
TFF1 ER binding site or promoter regions of the
SCN2A1 and RPL13A genes (n = 3).
(H) Venn diagram of gH2AX, A3B, and ER binding
events from ChIP-seq experiments for estrogen-
treated cells. Individual peaks were identified us-
ing the same peak-calling algorithm (MACS1.4)
using identical settings.
(I) Analysis of the relative enrichment of tran-
scription factor binding sites was used to generate
a Z score, which is represented by the size of the
motif in the word cloud.
(J) Genome browser snapshots of gH2AX ChIP-
seq in MCF7 cells treated with estrogen, H2O2, or
vehicle.
(K) Heatmap showing clustered binding signals for
regions enriched in gH2AX for all treatment con-
ditions. The windows represent ±5.0-kb regions
from the center of the ER binding events. The color
scale shows relative enrichment based on raw
signal.
(L) Average signal intensities of gH2AX ChIP-seq
binding events centered on ER binding regions
are shown for the different treatments. Signal in-
tensity is a normalized count of individual, non-
redundant ChIP fragments at single ER binding
sites identified with the MACS1.4 peak-calling
algorithm.dU excision by UNG results in the generation of DNA strand
breaks that can be repaired by the NHEJ pathway (Kotnis
et al., 2009; Nowarski et al., 2012). Moreover, high-level A3G
expression in leukemia cells promotes DNA strand breaks (Kot-
nis et al., 2009; Nowarski et al., 2012). Finally, A3B overexpres-
sion promotes gH2AX (Burns et al., 2013a), which is activated
at DNA strand breaks (DSB) and is thus a marker for DSB. We
reasoned, therefore, that targeted A3B-mediated cytidine deam-
ination and dU excision by UNG could promote DSB generation
at ER/A3B enhancers. If so, then estrogen treatment of breast
cancer cells should be sufficient to cause DSBs in breast cancer
cells. Indeed, treatment of MCF7 cells with estrogen induced
gH2AX within 10 min (Figures 4D and 4E). gH2AX induction114 Cell Reports 13, 108–121, October 6, 2015 ª2015 The Authorsrequired ER, since synthetic ER ligands also induced gH2AX
(Figures S5A andS5B), while treatment with anti-estrogens 4-hy-
droxytamoxifen (OHT) or fulvestrant (FUL) prevented estrogen
induction of gH2AX (Figures 4F and S5C), as did transfection
with ER siRNA (Figure S5D). Estrogen similarly induced gH2AX
in an ER-dependent manner in T47D cells (Figures S5E and
S5F), but not in the ER- MDA-MB-231 cells (Figure S6A). How-
ever, estrogen stimulation of gH2AX was possible in MDA-MB-
231 cells ectopically expressing ER.
Estrogen induced gH2AX required DNA-PK and ATM activities
and the gH2AX foci co-localized with 53BP1 (Figures S5G and
S5H), verifying that estrogen treatment promotes DSBs. We
used ChIP for gH2AX to determine if the DSBs localize to ER
and A3B binding regions. Estrogen treatment stimulated gH2AX
at the ER/A3B binding region in the TFF1 gene, but no gH2AX
enrichment was observed at the promoter of a gene that is not
expressed in MCF7 cells (SCN2A) (Ju et al., 2006), nor was
gH2AX enrichment observed at the non-ER target gene
RPL13A, which is expressed in MCF7 cells (Figure 4G). We un-
dertook gH2AX ChIP-seq to determine the global distribution
of gH2AX following estrogen treatment (Figure S7A). Peak calling
identified 17,892 gH2AX binding events in the estrogen-treated
samples. Using the definition that a binding region must overlap
by at least one base pair, 54% (9,637/17,892) of gH2AX regions
co-localized with A3B and/or ER binding events, with two-thirds
(64%, 6,173/9,637) of these regions co-localizing to A3B and ER
co-incident binding events (Figure 4H). Motif enrichment anal-
ysis confirmed that the gH2AX regions are highly enriched for
ER (ESR1) binding motifs (Figure 4I). Correlation coefficient
values for the raw sequencing data confirmed the co-localization
of gH2AX regions with A3B (r2 = 0.69) and ER (r2 = 0.70) binding
events (Figure S7B). Genomic loci exemplifying gH2AX at A3B
and ER binding regions are shown in Figure 4J.
Aligning the gH2AX peaks showed very little enrichment for
gH2AX in vehicle-treated cells at ER binding regions (Figures
4K and 4L). H2O2 treatment, which induced gH2AX, also did
not result in much enrichment of gH2AX at ER binding regions.
Indeed, co-treatment with H2O2 and estrogen reduced gH2AX
at ER regions, compared with estrogen alone. Indeed, themajor-
ity of gH2AX regions induced by estrogen were enriched for ER
and A3B binding (Figure S7C). There was some enrichment for
ER and A3B sites in gH2AX regions that were common to all
treatments. However, there was very little overlap with ER or
A3B sites for gH2AX regions present in vehicle treated, or
following H2O2 treatment, indicating that estrogen/ER induced
gH2AX occurs at sites that are quite distinct from those caused
by DNA-damaging agents.
As described above, the greater part of ER and A3B binding
occurs at distal regions. Active regulatory regions such as en-
hancers and promoters carry specific epigenetic modifications
including H3K27ac (enhancers and promoters), H3K4me1
(enhancer specific), and H3K4me3 (promoter specific) (ENCODE
Project Consortium, 2012). Interestingly, A3B was found at 93%
of active enhancers and 7% of active promoters (Figure S7D).
This was confirmed by strong enrichment for BRD4 and p300,
two ubiquitous co-activators found at active regulatory elements
(Hnisz et al., 2013). In addition, using recently published GRO-
seq data (Hah et al., 2013), we could identify bi-directional tran-
scription at a subset of distally bound A3B sites, indicating the
possibility of eRNA synthesis at these elements.
APOBEC3BAction at ERTargetGenesCauses Transient
DNA Strand Breaks That Are Repaired by NHEJ
Our results demonstrate that A3B induces C-to-U transitions and
promotes UNG, DNA-PK, and Ku70 recruitment to ER binding
regions (Figures 4A and 4B). We have also shown that estro-
gen/ER rapidly induces gH2AX globally at ER and A3B binding
regions. These findings imply that A3B action is required for
DSB generation at ER binding regions. Indeed, A3B knockdown
blocked estrogen-induced gH2AX in MCF7 cells (Figures 5A,
5B, and S5D) and prevented gH2AX at ER binding sites in theCTFF1 and PDZK1 genes (Figure 5C). Similarly, UNG was
required, as its knockdown also inhibited estrogen induction of
gH2AX (Figure S5I). Moreover, estrogen induction of gH2AX in
MDA-MB-231 cells expressing ER required A3B (Figures S6B
and S6C). A3B was also necessary for optimal expression of
ER-regulated genes in the ER-expressing MDA-MB-231 lines
(Figure S6D).
Next, we used biotin-16-deoxyuridine triphosphate (dUTP)
labeling of DSBs with terminal deoxynucleotide transferase
(TdT) (Ju et al., 2006) followed by biotin ChIP and real-time
PCR to directly determine if DSBs are formed at ER/A3B binding
regions. Real-time PCR using primers located 30 to the region in
the TFF1 gene to which the great majority of C-to-U transitions
mapped showed 6-fold enrichment over the vehicle control
within 10 min of estrogen addition (Figure 5D). DSBs in this re-
gion were reduced to basal levels by 60 min, in general agree-
ment with the reduction in gH2AX over this time frame. A
similar rapid but transient induction of DSBs was observed for
other ER target genes, but there were no detectable DSBs
at the non-expressed SCN2A1 gene promoter, or at a region
2 kb 50 to the ER binding region in TFF1 (TFF1 control). PCR
using primers A/C, which amplify across the region containing
the C-to-U transitions failed to show estrogen stimulation of
DSBs, indicating that estrogen induces DSBs within the
region of the TFF1 gene that is characterized by A3B-mediated
C-to-U transitions (Figure 5E). Estrogen induction of DSBs was
prevented if the cells were transfected with A3B siRNAs (Figures
5E and 5F).
A3B Is Required for Histone Modification and
Recruitment of Chromatin Remodeling Factors at ER
Binding Regions
Transcription factors regulate gene expression by promoting the
ordered recruitment of diverse complexes that modify and
remodel chromatin, leading to transcription initiation. Recent
studies show that DNA repair factors regulate gene expression
by aiding chromatin remodeling (Fong et al., 2013). A3B knock-
down prevented estrogen stimulation of histone modifications
associated with transcription at ER target genes (Figures 6A
and 6B). Importantly, H2AX phosphorylation at serine-139
(gH2AX) promotes chromatin recruitment of BRG1, the catalytic
subunit of the SWI/SNF ATPase-dependent chromatin remodel-
ing complex (Lee et al., 2010). In agreement with a model in
which A3B-mediated cytidine deamination leads to H2AX activa-
tion, A3B knockdown prevented BRG1 recruitment (Figures 6C
and 6D). A3B knockdown also inhibited PolII recruitment to the
TFF1 and GREB1 genes. Interestingly, the estrogen-stimulated
gH2AX co-localizedwith activated (phosphorylated) PolII, further
evidence that the estrogen/ER and A3B regulated DSB forma-
tion occurs of transcriptionally active chromatin. In addition to
regulating histone modification and recruitment of chromatin re-
modelers, A3B was required for PolII recruitment to ER/A3B
binding regions (Figures 6E and 6F). The importance of H2AX
activation was underscored by the fact that treatment with the
DNA-PKcs inhibitor NU7441 or the ATM inhibitor KU55933
inhibited histone modification, as well as BRG1 and PolII recruit-
ment at ER target genes (Figures 6G–6M). Note that these treat-
ments did not affect A3B and ER recruitment.ell Reports 13, 108–121, October 6, 2015 ª2015 The Authors 115
Figure 5. Estrogen-Induced DNA Strand Breaks Are Dependent on A3B
(A) Hormone-depleted MCF7 cells were used for all experiments. Cells transfected with siA3B or siControl were treated with estrogen. Shown are representative
images for gH2AX staining.
(B) The average gH2AX foci number per cell in 100 cells from five replicates ± SEM.
(C) ChIP assay with MCF7 cells transfected with A3B or control siRNA.
(D) Estrogen was added and cells end labeled by incubation with biotin-16-dUTP in the presence of terminal deoxynucleotide transferase (TdT). ChIP was
performed with a biotin antibody.
(E and F) Estrogen was added following siRNA transfections for 10 min. Biotin end labeling was performed as in (D).
(C–F) n = 3; *p < 0.001; NS, not significant.DISCUSSION
The molecular mechanisms by which ER drives breast cancer
has identified transcription factors that direct ER to active en-
hancers (Magnani et al., 2011) and revealed that ER controls
the coordinated recruitment of chromatin remodeling and modi-
fication proteins and the transcription machinery that together116 Cell Reports 13, 108–121, October 6, 2015 ª2015 The Authorsfacilitate the program of estrogen-responsive gene expression
(Me´tivier et al., 2006). There is also gathering evidence that
many protein complexes that sense and repair DNA damage
are important for regulation of gene expression by ER and other
transcription factors, their recruitment aiding chromatin modifi-
cation/remodeling to promote gene activation (Fong et al.,
2013). For example, the BER protein thymine DNA glycosylase
Figure 6. A3B Is Required for Chromatin
Remodeling and Activating Histone Modifi-
cations at ER Enhancers
All experiments were undertaken with hormone-
depleted MCF7 cells.
(A andB) ChIP for histone H3 andH3modifications
associated with gene activation, was performed
following estrogen addition to cells transfected
with siA3B or control siRNA (n = 3, *p < 0.001).
(C–E) ChIP for BRG1, ER, and PolII followed by
real-time for A3B/ER binding sites in TFF1,
PDZK1, and GREB1.
(F) Cells were treated with estrogen for 10 min and
immunostained for gH2AX (green) and PolII (red).
(G–M) 5 mM NU7441 (DNA-PKcs inhibitor) or
KU55933 (ATM inhibitor) was added for 1 hr fol-
lowed by estrogen addition. ChIP was performed
as above (n = 3, *p < 0.001).
(N) Cells were treatedwith NU7441 or KU55933 for
1 hr, at which point estrogen was added. Real-
time RT-PCR was performed with RNA prepared
after 4 hr (n = 3; *p < 0.001).acts as a co-activator for ER and promotes recruitment of the
p160 co-activators and the CBP/p300 histone acetyltransferase
(Lucey et al., 2005; Tini et al., 2002). One reason advanced for the
function of DNA repair proteins in gene regulation is that they
may aid in relieving torsional stress generated by transcription-
induced DNA supercoiling (Ma and Wang, 2014). Movement of
RNA polymerase (RNAP) along the DNA template during tran-
scription generates over-winding (positive DNA supercoiling) in
front and negative DNA supercoiling behind it. Failure to resolve
DNA supercoiling will ultimately affect transcription. Additionally,
generation of DNA supercoiling at one promoter can affect tran-Cell Reports 13, 108–121scription from a distal promoter, so-
called topological promoter coupling
(Ma and Wang, 2014). Given the recent
identification of active transcription at
enhancer regions, which generates
eRNAs, RNAP procession is also likely
to create torsional stress at enhancer
regions, which might contribute to
inhibition of transcription from coupled
gene promoters. Furthermore, regulation
of transcription by enhancer regions
entails communication between distal
enhancers and regulated promoters
through chromatin looping, a process
that is also influenced by DNA supercoil-
ing (Kulaeva et al., 2012). Thus, DNA
topoisomerases, which relax negative
and positive DNA supercoils, are impor-
tant in transcription regulation. Indeed,
ER- and androgen receptor (AR)-induced
transcription in breast and prostate can-
cer involves transient DSBs generated
by TOP1 and TOP2 (Ju et al., 2006; Puc
et al., 2015). Activation of the LSD1 his-
tone demethylase by ER binding pro-moted 8-oxoguanine modification of DNA and recruitment of
8-oxoguanine-DNA glycosylase and BER to stimulate chromatin
changes that facilitate interaction between ER-regulated gene
enhancers and promoters (Perillo et al., 2008). Thus, DSB forma-
tion and their resolution is an important component of the regu-
lation of gene expression by of ER.
Here, we report an alternative mechanism for transcription of
ER-regulated genes in which DSBs are generated in a process
initiated by estrogen-ER-dependent recruitment of A3B. The
importance of A3B in ER action is implied by our observation
of the exceptionally high genome-wide co-localization of ER, October 6, 2015 ª2015 The Authors 117
Figure 7. Model for A3B-Mediated Activation of ER Enhancers
toward Regulation of ER Target Gene Expression
Estrogen binding to ER promotes its recruitment to ER enhancers. A3B, re-
cruited to these regions through interaction with ER, provides enzymatic
conversion of C to U. Generation of U:G mismatches promotes DNA nicks
through the action of UNG and AP endonuclease, resulting in DNA cleavage
and repair by the non-homologous end-joining DNA repair pathway. Induction
of transient C-to-U changes stimulates chromatin modification and remodel-
ing and PolII recruitment to facilitate expression of ER target genes.and A3B binding regions. Moreover, we show that estrogen
treatment causes rapid induction of DSBs, as demonstrated by
gH2AX activation. Importantly, the majority of estrogen-induced
gH2AX occurs at ER and A3B binding regions, and we have
shown that gH2AX induction is dependent on A3B. Our work
demonstrates that A3B directs cytidine deamination at ER bind-
ing regions to facilitate DSBs through activation of BER and sub-
sequent repair of these lesions by the NHEJ pathway. The critical
role of A3B action in the regulation of gene expression by ER is
established by its requirement for breast cancer cell growth
in vitro and in vivo. Based on these findings, we propose that
the A3B-mediated generation of C-to-U changes and activation
of DNA repair pathways facilitates chromatin remodeling and
enhancer/promoter interaction. In support of this, A3B is
required for SWI/SNF recruitment, activating histone modifica-
tions and PolII recruitment to ER binding regions (a schematic
model is shown in Figure 7).
Interestingly, DNA damage by irradiation or with the use of
models in which DNA DSBs are locally induced with restriction
enzymes such as I-SceI has demonstrated that ATM promotes
dynamic chromatin condensation and transcriptional silencing
at DSBs (Khurana et al., 2014; Shanbhag et al., 2010). DNA-
PKcs can repress transcription (Pankotai et al., 2012), but its
recruitment to transcription-factor-promoted DSBs stimulates
transcription (Ju et al., 2006). As proposed by Tjian and col-
leagues (Fong et al., 2013), transient DSB generation by tran-118 Cell Reports 13, 108–121, October 6, 2015 ª2015 The Authorsscription factors may limit gH2AX accumulation and spreading
to check retention of DNA repair factors and thus control the
extent of the DDR response. In agreement with this model,
DNA DSB-induced H2AX phosphorylation is spread over large
domains around the DSB (Iacovoni et al., 2010). This contrasts
with the restricted gH2AX distribution induced by A3B recruit-
ment to ER binding regions observed here. Thus, the mode of
ATM and DNA-PKcs recruitment appears to determine the effect
of DSBs on transcription.
Proteins that preferentially bind to DNA sequences containing
methylcytosine (mC) to regulate chromatin and control gene
expression are well described. Importantly, proteins that bind
to other CpG modifications, including 5-hydroxymethlycytosine
(hmC), 5-formylcytosine (fC), and 5-carboxylcytosine (caC) are
now being identified and include not only DNA repair factors
but also chromatin regulators and transcription factors (Iurlaro
et al., 2013; Spruijt et al., 2013). Our findings allow that there
may be transcription regulatory proteins that interact with DNA
containing dU and that are therefore recruited upon A3B-medi-
ated cytidine deamination at gene enhancers, an intriguing pos-
sibility that may deserve further investigation.
Recent studies show that cytidine deamination is an important
feature of the mutational landscape in breast (Alexandrov et al.,
2013; Burns et al., 2013a; Nik-Zainal et al., 2012), ovarian (Leo-
nard et al., 2013), lung (de Bruin et al., 2014), and other cancers
(Burns et al., 2013b; Roberts et al., 2013), with high-level expres-
sion of A3B, and experimental studies indicate that A3Bmay be a
key driver of such mutational signatures (Burns et al., 2013a;
Taylor et al., 2013). It is tempting to speculate that the cytidine-
deaminase-associated mutational landscapes in breast cancer
might be enriched at ER/A3B binding regions. In support of
this possibility, AR was shown to promote DNA DSBs to aid
intra- and inter-chromosomal translocations in prostate cancer
cells, one mechanism for which involved the hormone-depen-
dent recruitment of AID (Lin et al., 2009). Determination of the
global ER binding profiles by ChIP-seq analysis of breast tumors
has shown that there is a high level of plasticity in ER binding in
breast cancer (Ross-Innes et al., 2012), such that investigation of
any association between A3B/ER binding regions and somatic
mutations may entail whole-genome sequencing, coupled with
ER and A3B ChIP-seq in the same tumor. Interestingly, however,
gene regulatory regions can be characterized by low levels of
somatic mutations in cancer in the absence of additional defects
in DNA repair (Polak et al., 2014). Our results suggest that
activation of DNA repair pathwaysmay protect enhancer regions
from A3B-dependent mutagenesis. It would be important there-
fore to investigate the involvement of defects in BER and/or
NHEJ in cancer mutational landscapes that have been ascribed
to A3B.
In summary, our results identify an important role for A3B as a
regulator of ER-mediated gene expression in breast cancer, with
potential as a therapeutic target in ER+ breast cancer. To
advance this possibility, it will be important to extend our findings
to studies that identify global A3B regulated genes in breast can-
cer cell lines, as well as in tumor samples. Moreover, as A3B is
widely expressed in other cancers, it is likely that A3B inhibition
represents an important therapeutic approach to inhibit regu-
lated transcription in other cancer types.
EXPERIMENTAL PROCEDURES
Cell Lines, Plasmids, Antibodies, and Real-Time RT-PCR Assays
Cell lines were obtained from and cultured in media recommended by ATCC.
MCF7, T47D, SkBr3, COS-1 and HeLa cells were grown in DMEM containing
10% fetal calf serum (FCS). MDA-MB-231 cells stably expressing ER have
beendescribed (Bhat-Nakshatri et al., 2004). Hormone depletionwas achieved
by culturing cells for 72 hr in DMEM lacking phenol red and containing 5%
dextran-coated charcoal-stripped FCS. Plasmids, antibodies, and real-time
PCR primers are detailed in the Supplemental Experimental Procedures.
Reporter Gene Assays
Hormone-depleted COS-1 cells were transfected with ERE3-TATA-luc, pRL-
TK, together with ER and hemagglutinin (HA)-tagged A3B. Estrogen (10 nM)
or an equal volume of ethanol (vehicle) was added 5 hr following transfection.
Transfection methodology and luciferase measurements were performed as
described previously (Lai et al., 2013). Reporter gene assays in HeLa cells
following transfection with ER, A3B, and myc-UGI-NLS were undertaken as
above.
siRNA
Cells were transfected with siRNA using Lipofectamine RNAiMax (Invitrogen).
For collecting RNA and protein, 10 nM estrogen was added after 48 hr; RNA
and protein lysates were prepared after a further 12 hr. Cell growth was deter-
mined using the sulforhodamine B (SRB) assay, as described previously (Lai
et al., 2013). Details of siRNAs are provided in the Supplemental Experimental
Procedures.
MCF7 Human Tumor Xenografts
10 mM siRNA prepared with the atelogene in vivo siRNA transfection kit
(Koken, Japan) was injected weekly directly into tumors. Tumor volumes
were determined twice weekly. At the end of the experiment, protein lysates
were prepared from half of each tumor by homogenization in RIPA buffer.
RNA was prepared from the remaining halves of each tumor using the
RNAeasy kit (QIAGEN). The study was undertaken under the auspices of a
UK Home Office project license, using approved procedures.
Gene Expression
Total RNA was prepared and real-time RT-PCR was performed as described
previously (Ngan et al., 2009), using TaqMan gene expression assays fromABI.
Immunoprecipitations
Immunoprecipitations were performed as described previously (Lopez-Garcia
et al., 2006).
Immunofluorescence
Cells were cultured on glass coverslips in phenol red-free DMEM containing
5% double charcoal-stripped FCS for 3 days before the addition of ligands.
Cells were fixed and incubated with antibodies, as described in the Supple-
mental Experimental Procedures. Images were acquired using a Zeiss
LSM510 confocal microscope. Images were analyzed using Fuji Image J
(NIH) and CellProfiler (Broad Institute) for quantification of staining.
ChIP
ChIP was performed as described previously (Lai et al., 2013), using 10 mg of
antibody and 100 ml of Protein A Dynalbeads (10002D; Invitrogen). Control
ChIP was performed by the addition of mouse immunoglobulins (IgG).
ChIP and Solexa Sequencing
ChIP DNA was amplified as described (Schmidt et al., 2009). Sequences were
generated by the IlluminaHiseq 2000 genome analyzer (using 50 bp reads) and
aligned to the Human Reference Genome (assembly hg19, February 2009)
using Bowtie 1.0. The model-based analysis for ChIP-seq (MACS) peak caller
version 1.4 (Zhang et al., 2008) was used to identify enriched regions of the
genome by comparison to an input sample. MACS was used in the default
setting with a p value threshold of 105. To call stimuli specific peaks, we
used bedtool to subtract or concatenate BED files generated by MACS. TheCnumber of reads obtained, percentage of reads aligned, peaks called, and
additional analysis methods are detailed in the Supplemental Experimental
Procedures.
Biotin Labeling of DSB
Biotin labeling was performed as described previously (Ju et al., 2006) and
detailed in the Supplemental Experimental Procedures.
3D-PCR, Cloning, and Sequencing
3D-PCR was carried out as described elsewhere (Suspe`ne et al., 2005).
Genomic DNA was prepared using the Invitrogen genomic extraction kit.
Products from the second round PCR were purified using the QIAGEN PCR
purification kit, cloned into the TOPO-TA cloning vector (Invitrogen), and
sequenced with the T7 sequencing primer.
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